Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India has taken the lead in recognising NAFLD as a major non-communicable disease
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Quinidine Sulphate helps manage rare irregular heartbeat conditions
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
This license will enable Abbott to enhance access to this novel therapy to more patients across India
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Subscribe To Our Newsletter & Stay Updated
